Meletios A. Dimopoulos

4 weeks ago | tandfonline.com | Sagar Lonial |Meletios A. Dimopoulos |Jesus G Berdeja |Paul Richardson

ABSTRACTMultiple myeloma (MM) is a plasma cell neoplasm that stems from the malignant transformation of clonal plasma cells. It is characterized by multiple periods of remission and relapse requiring multiple lines of therapy, with response to treatment and survival decreasing with each successive relapse. To achieve deep and durable responses in relapsed/refractory MM (RRMM), novel treatments are required.

Nov 8, 2024 | onclive.com | Meletios A. Dimopoulos

CommentaryVideoNovember 8, 2024Author(s):Fact checked by:,Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Oct 23, 2024 | onclive.com | Meletios A. Dimopoulos

CommentaryVideoOctober 23, 2024Author(s):Meletios A. Dimopoulos, MD, discusses patient-reported outcomes with BPd in pretreated patients with relapsed/refractory multiple myeloma. Meletios A.

Dec 7, 2023 | nature.com | Elias K. Mai |Hans Salwender |Marc S. Raab |Katia Mancuso |Meral Beksac |Ullrich Graeven | +6 more

AbstractEarly morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both.